These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 22682987)

  • 21. Tardive tremor.
    Storey E; Lloyd J
    Mov Disord; 1997 Sep; 12(5):808-10. PubMed ID: 9380072
    [No Abstract]   [Full Text] [Related]  

  • 22. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era.
    Basu A; Meltzer HY
    Schizophr Res; 2006 Sep; 86(1-3):99-109. PubMed ID: 16753284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased high-sensitivity C-reactive protein levels in Taiwanese schizophrenic patients.
    Lin CC; Chang CM; Liu CY; Huang TL
    Asia Pac Psychiatry; 2013 Jun; 5(2):E58-63. PubMed ID: 23857813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia.
    Fan X; Pristach C; Liu EY; Freudenreich O; Henderson DC; Goff DC
    Psychiatry Res; 2007 Jan; 149(1-3):267-71. PubMed ID: 17112596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment.
    Sarandol A; Kirli S; Akkaya C; Ocak N; Eroz E; Sarandol E
    J Psychopharmacol; 2007 Nov; 21(8):857-63. PubMed ID: 17715203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients.
    Löffler S; Löffler-Ensgraber M; Fehsel K; Klimke A
    Int Clin Psychopharmacol; 2010 Mar; 25(2):101-6. PubMed ID: 20101184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-sectional prevalence of metabolic syndrome in Korean patients with schizophrenia.
    Kang SH; Kim KH; Kang GY; Lee KH; Kim KK; Soh M; Ahn KJ; Kim SH; Lee JI
    Schizophr Res; 2011 May; 128(1-3):179-81. PubMed ID: 21303730
    [No Abstract]   [Full Text] [Related]  

  • 30. [Assessment and control of metabolic and cardiovascular risk in patients with schizophrenia].
    Rodríguez-Artalejo F; Baca E; Esmatjes E; Merino-Torres JF; Monereo S; Moreno B; Mories T; Roca M; Salvador J; Sanmartí A
    Med Clin (Barc); 2006 Oct; 127(14):542-8. PubMed ID: 17145003
    [No Abstract]   [Full Text] [Related]  

  • 31. Diabetes, physical activity participation and exercise capacity in patients with schizophrenia.
    Vancampfort D; De Hert M; Sweers K; De Herdt A; Detraux J; Probst M
    Psychiatry Clin Neurosci; 2013 Sep; 67(6):451-6. PubMed ID: 23941126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year.
    Schorr SG; Slooff CJ; Bruggeman R; Taxis K
    J Psychiatr Res; 2009 Sep; 43(13):1106-11. PubMed ID: 19398113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia.
    Said MA; Sulaiman AH; Habil MH; Das S; Bakar AK; Yusoff RM; Loo TH; Bakar SA
    Singapore Med J; 2012 Dec; 53(12):801-7. PubMed ID: 23268153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
    Kawabe K; Horiuchi F; Ueno S
    Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations between expiratory spirometry parameters and limitations in daily life activities in patients with schizophrenia.
    Vancampfort D; Probst M; Stubbs B; Soundy A; De Herdt A; De Hert M
    Gen Hosp Psychiatry; 2014; 36(2):172-6. PubMed ID: 24360836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical decision making in antipsychotic drug choice for schizophrenia.
    Hamann J; Langer B; Leucht S; Busch R; Kissling W
    Am J Psychiatry; 2004 Jul; 161(7):1301-4. PubMed ID: 15229068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycinamide prevents MK-801-induced hyperactivity and deficits in object recognition memory in an animal model of positive and cognitive symptoms of schizophrenia.
    Basurto E; Flores OG; Hoffman KL
    Schizophr Res; 2015 Aug; 166(1-3):349-50. PubMed ID: 25823398
    [No Abstract]   [Full Text] [Related]  

  • 38. Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications.
    Jerrell JM; McIntyre RS; Tripathi A
    Clin Schizophr Relat Psychoses; 2010 Oct; 4(3):161-8. PubMed ID: 20880826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring for metabolic complications associated with atypical antipsychotics.
    Farver D
    S D J Med; 2005 Feb; 58(2):53-4. PubMed ID: 15756776
    [No Abstract]   [Full Text] [Related]  

  • 40. A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
    Li CH; Shi L; Zhan GL; Rao SZ; Zhang H
    Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2136-40. PubMed ID: 23893178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.